RLMD: HC Wainwright Initiates Buy
HC Wainwright & Co. initiates coverage on Relmada Therapeutics with a buy rating and a price target of $12
HC Wainwright & Co. initiates coverage on Relmada Therapeutics with a buy rating and a price target of $12
HC Wainwright & Co. initiates coverage on Relmada Therapeutics with a buy rating and a price target of $12
HC Wainwright & Co. initiates coverage on Relmada Therapeutics with a buy rating and a price target of $12